系统综述:预测非小细胞肺癌患者立体定向消融放疗后局部复发的影像学特征
该系统综述纳入32项研究,汇总非小细胞肺癌患者接受立体定向消融放疗后,CT与FDG-PET影像学特征预测局部复发的价值,局部复发发生率为13%(222/1726)。CT上≥3个高危特征或SABR后≥12个月出现增大密度影高度可疑局部复发;FDG-PET上12个月内SUVmax较基线相对下降<5%或12个月后SUVmax>5、SUVmean>3.44可提示局部复发。影像组学证据有限,结论需进一步研究验证。
要点
- CT上≥3个高危特征或SABR后≥12个月出现增大密度影高度可疑局部复发。
- FDG-PET上12个月内SUVmax较基线相对下降<5%或12个月后SUVmax>5、SUVmean>3.44可提示局部复发。
- 支持影像组学特征预测局部复发的证据有限。
核心结论
- 该研究识别出局部复发与放射性肺损伤相比的共同特征,可能有助于SABR后局部复发的早期准确检测;需进一步研究验证这些发现。
研究设计与样本
- 检索MEDLINE、EMBASE、PubMed数据库的已发表研究及Web of Science、Wiley Online、Science Direct数据库的会议摘要,纳入报告非小细胞肺癌患者SABR后FDG-PET或CT影像学特征及影像组学的研究,由2名作者独立审阅纳入研究。
主要发现
- 32项相关研究中局部复发发生率为13%(222/1726)。
- CT上某些大体影像表现及大小、直径、体积变化或肿块样实变体积连续3次增大的动态特征提示局部复发。
- CT上出现任何≥3个高危特征或SABR后≥12个月出现增大密度影这一单项高危特征高度可疑局部复发。
- FDG-PET上12个月内SUVmax较基线相对下降<5%或12个月后SUVmax>5、SUVmean>3.44可提示局部复发。
- 支持影像组学特征提示局部复发的证据有限。
关键数值与推荐
- CT高危特征:≥3个高危特征或SABR后≥12个月出现增大密度影高度可疑局部复发。
- FDG-PET:12个月内SUVmax较基线相对下降<5%或12个月后SUVmax>5、SUVmean>3.44可提示局部复发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 支持影像组学特征提示局部复发的证据有限。
- 需进一步研究验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Posttreatment surveillance for local recurrence (LR) after stereotactic ablative body radiotherapy (SABR) can include both fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT). Radiation-induced lung injury shares a similar appearance to LR after treatment, making the detection of LR on imaging difficult for clinicians. We aimed to summarize radiologic features of CT and FDG-PET predicting LR and to evaluate radiomics as another tool for detecting LR. METHODS AND MATERIALS: We searched MEDLINE, EMBASE, and PubMed databases for published studies and Web of Science, Wiley Online, and Science Direct databases for conference abstracts that had patient populations with non-small cell lung cancer and reported post-SABR radiologic features of FDG-PET or CT and radiomics from either FDG-PET or CT. Studies for inclusion were independently reviewed by 2 authors. RESULTS: Across 32 relevant studies, the incidence of LR was 13% (222/1726). On CT, certain gross radiologic appearances and kinetic features of changes in size, diameter, volume, or 3 consecutive rises in volume of masslike consolidation are suggestive of LR. **Particular regard should be made for the presence of any ≥3 high-risk features on CT or the individual high-risk features of enlarging opacity at ≥12 month's post-SABR as being highly suspicious of LR. On FDG-PET a relative reduction of <5% of maximum standardised uptake value (SUVmax) from baseline in the first 12 months or cut-offs of SUVmax >5 and SUVmean >3.44 after 12 months can indicate LR. There is limited evidence available to corroborate radiomic features suggestive of LR. CONCLUSIONS: This research has identified common features of LR compared with radiation-induced lung injury, which may aid in early and accurate detection of LR post-SABR; further research is required to validate these findings.
引用
- Lee K, Le T, Hau E, et al. A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2021. PMID: 34879247. doi:10.1016/j.ijrobp.2021.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。